Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of GFH312 in Healthy Chinese Subjects
NCT05991362Phase 1Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GFH312 in peripheral artery disease (PAD) (4 arms), sponsored by GenFleet Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 4, Time to Peak Drug Concentration at Day 4 and 9 more. Started Nov 2022; status: completed.
02
Drugs
GFH312
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT05991362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991362.